Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D.
Business Of Biotech
00:00
Biosonic CEO Dr. Francois Rijer: What Should Rest?
Biosonic CEO Dr. Francois Rijer: We want to be successful in the clinical trial this year and get the first patient for our chronic GVHD projector in the middle of this year. Well, like I said, we're running short on time. Are there are any questions that pop into your head that I should have asked you that I didn't? Did I did I miss anything major that you'd like to kind of squeeze in before we wrap things up here? Yeah, excellent. And thank you for your questions and good spirits in discussing with me. For sure.
Transcript
Play full episode
